Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics

Innovative high-content screening platform identified N-(2-butoxyphenyl)-3-(phenyl)acrylamides as novel antifibrotics.

[1]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[2]  S. Cook,et al.  Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis , 2019, Science Translational Medicine.

[3]  Naftali Kaminski,et al.  Single Cell RNA-seq reveals ectopic and aberrant lung resident cell populations in Idiopathic Pulmonary Fibrosis , 2019, bioRxiv.

[4]  M. Lindner,et al.  Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling. , 2019, Journal of visualized experiments : JoVE.

[5]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[6]  M. Lindner,et al.  Cell-surface phenotyping identifies CD36 and CD97 as novel markers of fibroblast quiescence in lung fibrosis. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[7]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..

[8]  B. Hinz,et al.  The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[9]  Florian Heigwer,et al.  Machine learning and image-based profiling in drug discovery , 2018, Current opinion in systems biology.

[10]  Thomas Blaschke,et al.  The rise of deep learning in drug discovery. , 2018, Drug discovery today.

[11]  M. Lindner,et al.  Distinct niches within the extracellular matrix dictate fibroblast function in (cell free) 3D lung tissue cultures. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[12]  O. Eickelberg,et al.  Cub domain-containing protein 1 negatively regulates TGF-β signaling and myofibroblast differentiation. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[13]  S. Nathan,et al.  Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4 , 2018, Scientific Reports.

[14]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[15]  M. Boshtam,et al.  Plasminogen Activator Inhibitor Type‐1 as a Regulator of Fibrosis , 2018, Journal of cellular biochemistry.

[16]  C. Henke,et al.  IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity , 2017, American journal of physiology. Lung cellular and molecular physiology.

[17]  P. Selzer,et al.  How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice. , 2017, Assay and drug development technologies.

[18]  C. Harrison,et al.  Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis , 2017, Front. Pharmacol..

[19]  H. Schiller,et al.  The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease , 2017, European Respiratory Journal.

[20]  M. Lindner,et al.  An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. , 2017, American journal of physiology. Lung cellular and molecular physiology.

[21]  Sebastian Thrun,et al.  Dermatologist-level classification of skin cancer with deep neural networks , 2017, Nature.

[22]  C. López-Otín,et al.  Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis , 2016, European Respiratory Journal.

[23]  M. Lindner,et al.  Surface proteome analysis identifies platelet derived growth factor receptor-alpha as a critical mediator of transforming growth factor-beta-induced collagen secretion. , 2016, The international journal of biochemistry & cell biology.

[24]  L. Richeldi,et al.  Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history , 2016, Respirology.

[25]  Ata Mahjoubfar,et al.  Deep Learning in Label-free Cell Classification , 2016, Scientific Reports.

[26]  R. Raines,et al.  Selective Inhibition of Collagen Prolyl 4-Hydroxylase in Human Cells. , 2016, ACS chemical biology.

[27]  S. Hauck,et al.  The Proteome of Native Adult Müller Glial Cells From Murine Retina* , 2015, Molecular & Cellular Proteomics.

[28]  N. Kaminski,et al.  FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. , 2015, American journal of respiratory and critical care medicine.

[29]  P. Spagnolo,et al.  Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. , 2015, Pharmacology and Therapeutics.

[30]  Oliver Eickelberg,et al.  Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair , 2015 .

[31]  P. Loria,et al.  Developing predictive assays: The phenotypic screening “rule of 3” , 2015, Science Translational Medicine.

[32]  B. Morrissey,et al.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. , 2015, Journal of thoracic disease.

[33]  Don C Rockey,et al.  Fibrosis--a common pathway to organ injury and failure. , 2015, The New England journal of medicine.

[34]  S. Turner,et al.  Proteomic Analysis of Altered Extracellular Matrix Turnover in Bleomycin-induced Pulmonary Fibrosis , 2014, Molecular & Cellular Proteomics.

[35]  M. Lindner,et al.  Multiplex Profiling of Cellular Invasion in 3D Cell Culture Models , 2013, PloS one.

[36]  S. Friedman,et al.  Therapy for Fibrotic Diseases: Nearing the Starting Line , 2013, Science Translational Medicine.

[37]  Kevin Weiss,et al.  Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. , 2012, American journal of respiratory and critical care medicine.

[38]  Alexandra Naba,et al.  Towards definition of an ECM parts list: an advance on GO categories. , 2012, Matrix biology : journal of the International Society for Matrix Biology.

[39]  O. Eickelberg,et al.  New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis , 2012, The Lancet.

[40]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[41]  M. Rogosnitzky,et al.  Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. , 2012, Anticancer research.

[42]  Thomas Delahais,et al.  Applying contribution analysis: Lessons from five years of practice , 2012 .

[43]  M. Ueffing,et al.  Direct comparison of MS‐based label‐free and SILAC quantitative proteome profiling strategies in primary retinal Müller cells , 2012, Proteomics.

[44]  Steven A. Carr,et al.  The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices , 2011, Molecular & Cellular Proteomics.

[45]  W. Lawson,et al.  Progress Toward Improving Animal Models for Idiopathic Pulmonary Fibrosis , 2011, The American journal of the medical sciences.

[46]  Thomas R. Cox,et al.  Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer , 2011, Disease Models & Mechanisms.

[47]  L. Gleaves,et al.  Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[48]  Daniel N Cox,et al.  Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. , 2010, Genomics.

[49]  Jong-Min Song,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome , 2010, European Respiratory Journal.

[50]  A. Feuchtinger,et al.  Deciphering Membrane-Associated Molecular Processes in Target Tissue of Autoimmune Uveitis by Label-Free Quantitative Mass Spectrometry* , 2010, Molecular & Cellular Proteomics.

[51]  Spencer J. Williams,et al.  Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. , 2009, Bioorganic & medicinal chemistry letters.

[52]  Markus Brosch,et al.  Accurate and sensitive peptide identification with Mascot Percolator. , 2009, Journal of proteome research.

[53]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[54]  C. Speer,et al.  The Role of Transforming Growth Factor β in Lung Development and Disease , 2004 .

[55]  F. Verrecchia,et al.  Transforming Growth Factor-β Signaling Through the Smad Pathway: Role in Extracellular Matrix Gene Expression and Regulation , 2002 .

[56]  Xia Lin,et al.  Smurf2 Is a Ubiquitin E3 Ligase Mediating Proteasome-dependent Degradation of Smad2 in Transforming Growth Factor-β Signaling* 210 , 2000, The Journal of Biological Chemistry.

[57]  C. Heldin,et al.  Specificity, diversity, and regulation in TGF‐β superfamily signaling , 1999 .

[58]  R. Hammer,et al.  Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. , 1997, The Journal of clinical investigation.

[59]  K. Csaky,et al.  Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. , 1997, The Journal of clinical investigation.

[60]  E. Ruoslahti,et al.  Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease , 1992, Nature.

[61]  T. Sasaki,et al.  Inhibition of prolyl hydroxylation during collagen biosynthesis in human skin fibroblast cultures by ethyl 3,4-dihydroxybenzoate. , 1987, The Journal of investigative dermatology.

[62]  M. Isaji,et al.  Selective inhibition of collagen accumulation by N-(3,4-dimethoxycinnamoyl)anthranilic acid (N-5') in granulation tissue. , 1987, Biochemical pharmacology.

[63]  K. Flaherty,et al.  A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis , 2018, American journal of respiratory and critical care medicine.

[64]  H. Collard,et al.  Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. , 2017, The Lancet. Respiratory medicine.

[65]  A. B. Pour,et al.  Tranilast: a review of its therapeutic applications. , 2015, Pharmacological research.

[66]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[67]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[68]  B. Crestani,et al.  Treatments for idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[69]  C. Ronco,et al.  Incidence, Risk Factors, and Outcome , 2014 .

[70]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[71]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[72]  佐藤 三佐子.  Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction , 2005 .